Bosentan

Revision as of 23:52, 18 November 2017 by Mholtz (talk | contribs) (Text replacement - "-->" to "→")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Endothelin receptor antagonists
  • Dosage Forms: tablet, tablet for oral suspension
  • Dosage Strengths: tablet: 62.5, 125 mg; tablet for oral suspension: 32mg
  • Routes of Administration: PO
  • Common Trade Names: Tracleer

Adult Dosing

  • 62.5-125mg PO BID

Pediatric Dosing

Safety/efficacy not established

Special Populations

  • Pregnancy Rating: X
  • Lactation risk: Infant risk cannot be ruled out
  • Renal dosing:
  • Hepatic dosing: avoid in moderate-severe disease

Contraindications

  • Allergy to class/drug
  • Concomitant administration with cyclosporine A or glyburide
  • Pregnancy or potential pregnancy

Adverse Reactions

Serious

  • Anemia
  • Cirrhosis, liver failure
  • Oligozoospermia
  • Edema, fluid retention

Common

  • Anemia
  • Respiratory tract infection

Pharmacology

  • Half-life: 5h
  • Metabolism: Hepatic: via CYP3A4 and CYP2C9
  • Excretion: Biliary, renal

Mechanism of Action

  • Dual endothelin receptor antagonist, inhibits vasoconstriction → vasodilation

Comments

See Also

References